Laurence Hurley

Laurence Hurley

Associate Director, BIO5 Institute
Professor, Medicinal Chemistry-Pharmaceutical Sciences
Professor, Medicinal Chemistry-Pharmacology and Toxicology
Professor, Cancer Biology - GIDP
Professor, BIO5 Institute
Primary Department
Department Affiliations
Contact
(520) 626-5622

Work Summary

Laurence Hurley's long-time research interest is in molecular targeting of DNA, first by covalent binders (CC-1065 and psorospermin), then as compounds that target protein–DNA complexes (pluramycins and Et 743), and most recently as four-stranded DNA structures (G-quadruplexes and i-motifs). He was the first to show that targeting G-quadruplexes could inhibit telomerase (Sun et al. [1997] J. Med. Chem., 40, 2113) and that targeting G-quadruplexes in promoter complexes results in inhibition of transcription (Siddiqui-Jain et al. [2002] Proc. Natl. Acad. Sci. U.S.A., 99, 11593).

Research Interest

Laurence Hurley, PhD, embraces an overall objective to design and develop novel antitumor agents that will extend the productive lives of patients who have cancer. His research program in medicinal chemistry depends upon a structure-based approach to drug design that is intertwined with a clinical oncology program in cancer therapeutics directed by Professor Daniel Von Hoff at TGen at the Mayo Clinic in Scottsdale. Dr. Hurley directs a research group that consists of a team of graduate and postdoctoral students with expertise in structural and synthetic chemistry working alongside students in biochemistry and molecular biology. NMR and in vivo evaluations of novel agents are carried out in collaboration with other research groups in the Arizona Cancer Center. At present, they have a number of different groups of compounds that target a variety of intracellular receptors. These receptors include: (1) transcriptional regulatory elements, (2) those involved in cell signaling pathways, and (3) protein-DNA complexes, including transcriptional factor-DNA complexes.In close collaboration with Dr. Gary Flynn in Medicinal Chemistry, he has an ongoing program to target a number of important kinases, including aurora kinases A and B, p38, and B-raf. These studies involve structure-based approaches as well as virtual screening. Molecular modeling and synthetic medicinal chemistry are important tools.The protein–DNA complexes involved in transcriptional activation of promoter complexes using secondary DNA structures are also targets for drug design.

Publications

Hurley, L. H. (1977). Pyrrolo(1,4)benzodiazepine antitumor antibiotics. Comparative aspects of anthramycin, tomaymycin and sibiromycin. Journal of Antibiotics, 30(5), 349-370.

PMID: 328469;Abstract:

The pyrrolo(1,4)benzodiazepine antibiotics comprise the antibiotics, anthramycin, tomaymycin, sibiromycin, dextrochrysin and the neothramycins A and B. Structure activity relationships indicate that in addition to a pyrrolo(1,4)benzodiazepine nucleus, these compounds also require a 10,11 carbinolamine and an unsaturated side chain at C-2 to retain their potent biological activities. The antibiotics within this group show antiviral and most significantly antitumor activity. Anthramycin and sibiromycin have been shown to have a wide range of antitumor activity in animal models, and in the case of anthramycin, activity against both solid and liquid tumors in man. Tryptophan, methionine and tyrosine supply the biosynthetic building blocks for anthramycin, tomaymycin and the aglycone moiety of sibiromycin. Parallel pathways from tryptophan, via kynurenine lead to the anthranilate moieties of these three antibiotics. Conversion of tyrosin, via dopa, to the C2 and C3-proline moieties of anthramycin, tomaymycin and sibiromycin involves meta cleavage of the aromatic ring of a tyrosine metabolite and loss of two aromatic carbon atoms. Addition of the pyrrolo(1,4)benzodiazepine antibiotics to bacterial or mammalian cells leads to a potent inhibition of RNA and DNA synthesis, while protein synthesis is virtually unaffected at these same antibiotic concentrations. Overwhelming evidence suggests that the pyrrolo(1,4)benzodiazepine antibiotics form a covalent linkage with DNA. No major modification of the pyrrolo(1,4)benzodiazepine antibiotics occurs upon reaction with DNA, and intact antibiotic can be released from their respective DNA adducts under certain acidic conditions. Structure activity relationships lead to the conclusion that the DNA reactive site on the pyrrolo(1,4)benzodiazepine antibiotics is the 10,11-carbinolamine. Most likely the covalent linkage with DNA involves a nucleophilic attack originating from a basic group on DNA at C-11 of the antibiotics resulting in loss of the conjugate acid.

Lubawy, W. C., Dallam, R. A., & Hurley, L. H. (1980). Protection against anthramycin-induced toxicity in mice by coenzyme Q10. Journal of the National Cancer Institute, 64(1), 105-109.

PMID: 6928034;Abstract:

Pretreatment of Swiss Webster mice with coenzyme Q10 (CoQ) markedly reduced the lethality of the antitumor antibiotic anthramycin as well as its ability to decrease ventricular weights. In tumor-bearing mice CoQ pretreatment did not produce any consistent alteration of radioactivity levels in blood, heart, tumor, lungs, kidneys, liver, muscles, brain, or spleen after [15-3H]anthramycin administration. Gross alterations in anthramycin distribution is probably not the mechanism by which CoQ alters the cardiotoxicity and lethality of anthramycin.

Hurley, L. H., Lee, C., McGovren, J., Warpehoski, M. A., Mitchell, M. A., Kelly, R. C., & Aristoff, P. A. (1988). Reaction of CC-1065 and select synthetic analogs with DNA. Biochemical Pharmacology, 37(9), 1795-1796.
Thurston, D. E., & Hurley, L. H. (1983). Tomaymycin. Drugs of the Future, 8(11), 945-946.
Sun, D., Hurley, L. H., & Harshey, R. M. (1996). Structural distortions induced by integration host factor (IHF) at the H' site of phage λ probed by (+)-CC-1065, pluramycin, and KMnO 4 and by DNA cyclization studies. Biochemistry, 35(33), 10815-10827.

PMID: 8718873;Abstract:

Integration Host Factor (IHF) is a sequence-specific DNA-bending protein that is proposed to interact with DNA primarily through the minor groove. We have used various chemical probes [(+)-CC-1065, a minor-groove-specific agent that alkylates N3 of adenine and traps bends into the minor groove; pluramycin, a minor-major-groove threading intercalator that alkylates N7 of guanine; KMnO 4, which reacts more strongly with bases in denatured DNA] to gain more information on the interaction of IHF with the H' site of phage λ. In addition to the 13-bp core consensus recognition element present at all IHF binding sites, the H' site also has an upstream AT-rich element that increases the affinity of IHF for this site. Our results reveal new details of IHF-DNA interaction at this site. Results with (+)-CC-1065 modification suggest that IHF interacts with the adenines on the 3'-side of the AT-rich element and likely induces a minor-groove bend in its vicinity, which in turn stabilizes the interaction. Pluramycin modification experiments suggest the presence of both short- and long-range structural perturbations (possible DNA unwinding events) on either side of the IHF contact region. Although IHF is known to induce a large bend in DNA at the H' site, no separation of base pairs was detected when the bent DNA was probed with KMnO 4. DNA cyclization studies indicate a large magnitude (approximately 180°) for the IHF-induced bend at the H' site, consistent with > 140° bend estimated by gel electrophoresis methods. These studies suggest that IHF-induced DNA bending is accompanied by the introduction of a DNA node, DNA unwinding, and/or by some other DNA distortion. An enhanced binding and stability of IHF was observed on small circular DNA.